Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
James Tsai, MD
Assistant Professor, Medicine
School of Medicine
Publications    Scholarly Journals--Published
  • Tsai JY, Ianniti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K, Safran H. Phase I study of docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer. American Journal of Clinical Oncology 2005;28(4):329-333. ( 0/2005 - Present )
  • Tsai JY, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Stuart K, Kennedy T, Safran H. Phase I/II study of docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer. Proc Am Soc Clin Oncol 2004;23:321(Abstract 4035). ( 0/2004 - Present )
  • Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Asiner S, Hameed M. Her-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Investigation 2004; 22(1): 16-24. ( 0/2004 - Present )
  • Tsai JY, Nadeem A, Safran H. Chemotherapy for pancreatic cancer. Medicine & Health, Rhode Island 2004; 87(5): 132-134. ( 0/2004 - Present )
  • Safran H, Dipetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R, Wanebo H, Constantino M, Hughes M, Maia C, Tsai JY, Pasquariello T, Pepperell JR, Cioffi W, Ng T, Reeder L, Adrian A, Kennedy T, Bapsi C, Choy H. Herceptin, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Investigation 2004; 22(5): 670-677. ( 0/2004 - Present )
  • Safran H, Iannitti D, Ramanathan R, Schwartz J, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes M, Maia C, Pasquariello T, King T, Tsai JY, Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investigation 2004;22(5): 706-712. ( 0/2004 - Present )
  • Tsai JY, Safran H. Status of treatment for advanced gastric carcinoma. Current Oncology Reports 2003; 5(3): 210-218. ( 0/2003 - Present )
  • Tsai JY, Iannitti D, Safran H. Combined modality therapy for pancreatic cancer. Seminars in Oncology 2003; 30(4 Suppl 9): 71-79. ( 0/2003 - Present )
  • Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Investigation 2003; 21(6): 887-896. ( 0/2003 - Present )
  • Tsai JY, Constantinou M, Khurshid H, Moore T, Rathore R, Maia C, Hughes M, Harrington D, Kennedy T, Safran H. A phase I study of capecitabine, docetaxel, and carboplatin in metastatic esophagogastric cancer. Proc Am Soc Clin Oncol 2003; 22:318 (Abstract 1276). ( 0/2003 - Present )
  • Barbashina V, Benevenia J, Aviv H, Tsai J, Patterson F, Aisner S, Cohen S, Fernandes H, Skurnick J, Hameed M. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases. Journal of Cancer Research and Clinical Oncology 2002; 128(11): 610-616. ( 0/2002 - Present )
  • Tsai JY, Ling M, Chang VT, Hwang SS, Kasimis BS. Hemorrhagic ascites: an unusual manifestation of prostate carcinoma. The American Journal of Medicine 2001; 111(3): 245-6. ( 0/2001 - Present )
  • Tsai JY, Aviv H, Benevenia J, Patterson F, Aisner S, Pliner L, Hameed M. Prognostic factors in osteosarcoma - role of Her-2/neu and p53: an immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) analysis. Proc Am Soc Clin Oncol 2001; 20: 295b (Abstract 2933) ( 0/2001 - Present )